Fifteen years of surveillance by the Australian Group for Antimicrobial Resistance (AGAR)

Graeme R Nimmo, Jan M Bell, Peter J Collignon, on behalf of the Australian Group for Antimicrobial Resistance

Abstract

The Australian Group for Antimicrobial Resistance (AGAR) has played a unique role in surveillance of antimicrobial resistance in Australia. It has a broad laboratory membership representing the major teaching hospitals in all Australian capitals and more recently major private pathology laboratories in most states. The use of an active surveillance strategy with standard methodology for collection and examination of clinically significant isolates has produced data accurately reflecting the changing prevalence of antimicrobial resistance in major hospitals as well as the community. AGAR has documented the spread of methicillin-resistant Staphylococcus aureus in Australian hospitals in the late 1980s and throughout the 1990s. Surveys of antimicrobial resistance in enterococci have monitored the emergence of vancomycin-resistant enterococci as an important nosocomial pathogen in Australia. AGAR has also conducted major national surveys of resistance in Streptococcus pneumoniae, community isolates of Staphylococcus aureus, Haemophilus influenzae and in the Enterobacteriaceae. These and other activities have given AGAR a unique perspective on emerging patterns of resistance in key pathogens in Australia. The recent extension of membership to include more private pathology laboratories may provide the opportunity to conduct more representative community based surveys. Commun Dis Intell 2003;27 Suppl:S47–S54.

Keywords: methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, Streptococcus pneumoniae, antimicrobial resistance

Introduction

The Australian Group for Antimicrobial Resistance (AGAR) has conducted surveillance of antimicrobial resistance in Australian teaching hospitals since 1986. AGAR membership has always includes very broad representation of the major teaching hospitals in all Australian capitals (Figure 1). The spread of methicillin-resistant Staphylococcus aureus (MRSA) was a major concern in the 1980s and surveillance of hospital staphylococcal infections was the first activity of AGAR. Periodic surveys of the prevalence of resistance in hospital isolates of S. aureus have now been conducted for 15 years. This represents the most complete prospective national description of the evolution of resistance in hospital isolates of S. aureus.

1. Director of Microbiology, Queensland Health Pathology Services, Brisbane, Queensland.
2. Senior Scientist, Microbiology and Infectious Disease, Women’s and Children’s Hospital, North Adelaide, South Australia.
3. Director of Microbiology and Infectious Diseases, Canberra Hospital, Garran, Australian Capital Territory.
The emergence of resistance in other groups of bacteria has prompted AGAR to conduct a number of organism specific surveys. An extensive study of resistance in *Haemophilus influenzae* was conducted prior to the introduction of vaccination for *H. influenzae* type b.\(^3\) The emergence of antimicrobial resistance in *Streptococcus pneumoniae* has caused worldwide concern and AGAR has been able to demonstrate over four surveys the trend towards multiple antimicrobial resistance and penicillin resistance in pneumococci in Australia.\(^4,5\) Ongoing surveys of antimicrobial resistance in enterococci have also been conducted in response to increasing interest in vancomycin-resistant enterococci. Changing patterns of resistance in the *Enterobacteriaceae* and the emergence of extended-spectrum ß-lactamases (ESBL) led to surveys of resistance trends in *Escherichia coli* and *Klebsiella pneumoniae*.

**Methods**

The AGAR surveys have been conducted prospectively with standardised methods for data collection, isolate collection and laboratory examination. Collections consisting of unique clinically significant sequential isolates, excluding duplicates and screening isolates, have been stored for future reference. Methods for identification, susceptibility testing and typing have been described in detail elsewhere.\(^1,2,3,4,5\) Standard quality control organisms were included in each susceptibility testing batch with results validated by a coordinating laboratory.

**Results**

**Resistance in *Staphylococcus aureus***

The first three surveys of the prevalence of resistance in teaching hospital isolates of *S. aureus* were conducted during 1986 and 1987.\(^2\) This first national study involved 14 teaching hospital laboratories in the national capital and all mainland state capitals. The study established that the prevalence of MRSA as a proportion of clinically significant isolates of *S. aureus* was 14.4 per cent. Annual surveys were conducted from 1989 to 1999 and the results have been published\(^6\) or submitted for publication. The total number of isolates collected in each year and the number of MRSA isolates are shown in
Figure 2. In the initial study most MRSA isolates were multiresistant. In the subsequent annual surveys MRSA was divided into two groups based on resistance to erythromycin, tetracycline, trimethoprim, gentamicin, rifampicin, fusidic acid, ciprofloxacin and mupirocin. Isolates which were resistant to three or more of the above were defined as multiresistant (mMRSA), and those resistant to less than three as non-multiresistant (nmMRSA). Data collected by AGAR and others showed that this latter non-multiresistant group appeared to arise more often in the community setting.\textsuperscript{6,7,8} The trends in prevalence of mMRSA and nmMRSA are shown in Figure 3. Both show marked and sustained increases in the late 1990s.

**Figure 2. Number of MRSA and MSSA isolates collected from 1989 to 1999**

**Figure 3. mMRSA and nmMRSA isolates collected from 1989 to 1999 as a proportion of all Staphylococcus aureus isolates**
Resistance in *Haemophilus influenzae*

Thirty-four laboratories were involved in the collection of 970 isolates of *H. influenzae* between 1988 and 1990. Minimal Inhibitory Concentrations (MICs) to 16 different antibiotics were determined. The overall rate of beta-lactamase production was 16 per cent but there was wide variation between the states. In Adelaide the rate was 4.5 per cent and in Canberra 28.6 per cent. There was also a marked difference between invasive strains (e.g., blood) and non-invasive strains (e.g., sputum). In invasive strains beta-lactamase production was 22.3 per cent but in respiratory tract isolates it was 35.3 per cent. Most strains were resistant to erythromycin. Variable resistance was seen to most other antibiotics with geographical differences as well as differences between invasive and non-invasive strains. In non-invasive strains the resistance to amoxicillin-clavulanate, chloramphenicol, tetracycline, trimethoprim and co-trimoxazole were 2.1 per cent, 1.8 per cent, 4.5 per cent, 12.2 per cent and 5.7 per cent respectively.

Resistance in *Streptococcus pneumoniae*

Antimicrobial resistance in *Streptococcus pneumoniae* has been monitored by the AGAR group in three survey periods, 1989, 1994 and 1999. Up to 100 consecutive clinically significant isolates were collected from each participating laboratory. All isolates collected for the 1994 and 1999 surveys had a penicillin MIC determined using Etest strips (AB Biodisk, Solna, Sweden). Erythromycin, tetracycline, chloramphenicol and co-trimoxazole were tested using disc diffusion. Penicillin resistance increased significantly between 1989 and 1994, however, this trend levelled out in 1999. Overall 86 per cent of invasive isolates and 75 per cent of non-invasive isolates were penicillin susceptible (MIC < 0.064 mg/L). High-level penicillin resistance (MIC > 1 mg/L) was found in 2.6 per cent of invasive isolates and 6.9 per cent of non-invasive isolates. Prevalence of penicillin resistance in invasive and non-invasive isolates in each state is shown in Figures 4 and 5. Multi-drug resistant strains were common with over 8 per cent resistant to three or more antimicrobial agents tested in 1994. In 1999, 6.8 per cent of invasive and 16.7 per cent of non-invasive isolates were multi-drug resistant. Another survey was conducted in 2002.

Figure 4. Proportion of penicillin resistance in *Streptococcus pneumoniae* in invasive isolates by state, 1999
Resistance in *Enterococcus* spp.

Two surveys to study the prevalence of antimicrobial resistance in *Enterococcus* spp. in hospitals were conducted, one in 1995 and another in 1999. For each study period, up to 100 consecutive clinically significant strains were identified and antimicrobial susceptibility tests performed using the participating institutions routine methods. Any strain demonstrating resistance to ampicillin, vancomycin or high level aminoglycoside resistance, and all non *E. faecalis* isolates were referred to a central testing laboratory for confirmation. Correct identification of *enterococci* to species level was problematic. The proportion of *E. faecium* increased from 5 per cent of all isolates in 1995 to nearly 10 per cent in 1999. No vancomycin resistance was detected in the first study period, however, in 1999, six (0.3%) strains were resistant. Ampicillin resistance in *E. faecium* increased from 57 per cent in 1995 to 77 per cent in 1999. Beta-lactamase production remains uncommon, with only one ß-lactamase producing *E. faecalis* detected.

During 1999, 18 institutions collected all enterococci isolated from blood cultures. Over 370 strains were isolated, of which 74 per cent were *E. faecalis*, and 20 per cent were *E. faecium*. Vancomycin-resistance was detected in 8 per cent of all *E. faecium* isolates. All were vanB and were from three institutions.

Resistance in *Escherichia coli* and *Klebsiella* spp.

Surveys of resistance and multi-resistance in *Escherichia coli* and *Klebsiella* spp. have been conducted biannually since 1992. Up to 50 isolates from each species were collected from 14–20 institutions throughout Australia. MICs to 14 antimicrobial agents (from 8 drug classes) were determined using a customised conventional MicroScan broth microdilution panel (Dade Behring, West Sacramento, California). In *E. coli* ampicillin resistance has been prevalent since the beginning of surveillance at approximately 50 per cent, while non-susceptibility to amoxicillin-clavulanate has remained at under 10 per cent. Multi-resistant *E. coli* (resistance to 4 or more drug classes) were uncommon (<4%). *K. pneumoniae* with an extended-spectrum ß-lactamase phenotype were prevalent in some institutions (Figure 6). Overall 8 per cent (range 0–26%) of *K. pneumoniae* were ceftazidime resistant (MIC > 1 mg/L). While most institutions demonstrated a decline in the number of *K. pneumoniae* with ESBL phenotypes since 1992, others have shown a steady increase since 1996. The number of *E. coli* that were ceftazidime resistant has remained steady at less than 1.5 per cent since 1992 (Figure 7).
1992 and 1998, the rate of ceftazidime resistant *K. pneumoniae* varied between 6–10 per cent with an increasing proportion of isolates with an MIC > 8 mg/L (Figure 7). Gentamicin resistance was also common in some institutions and closely paralleled ESBLs (Figure 8). Ciprofloxacin non-susceptibility (MIC > 1 mg/L) was uncommon in *E. coli* (< 1%). Ciprofloxacin non-susceptible *K. pneumoniae* decreased from 6–7 per cent in 1992–1996 to less than 3 per cent in 1998 (Figure 9). No carbapenem resistance has been detected. An increase in co-trimoxazole resistance (MIC > 8 mg/L) was observed between 1992 and 1994 (11% to 19%), but the level of resistance has since remained steady at approximately 20 per cent (data not shown).

**Figure 6. Extended-spectrum β-lactamase phenotype in *Escherichia coli* and *Klebsiella pneumoniae* in 20 institutions, 1992 to 1998**

![Graph showing extended-spectrum β-lactamase phenotype in *Escherichia coli* and *Klebsiella pneumoniae*.](image)

**Figure 7. Proportion of ceftazidime resistance in *Escherichia coli* and *Klebsiella pneumoniae*, 1992 to 1998**

![Graph showing proportion of ceftazidime resistance in *Escherichia coli* and *Klebsiella pneumoniae*.](image)
Future directions

AGAR will continue to publish surveys of antimicrobial resistance in bacteria causing serious health problems within Australia. Organisms of interest will include *Staphylococcus aureus*, pneumococcus, *Enterococcus* spp, *E.coli*, *Klebsiella* spp. and *Enterobacter* spp. As significant problems emerge in other organisms they will also be subject to survey where practicable. AGAR may also test organisms other than bacteria where there is currently little or no data but potential for antimicrobial resistance to compromise clinical care (e.g., fungi).
Additional major private laboratories have joined AGAR recently so that private pathology is now represented in each mainland state. This has given AGAR the ability to conduct valid surveys of community-acquired as well as health care-associated infections. Opportunities also exist for closer liaison with other groups involved in surveillance of health care-associated infections (e.g., with Australian Infection Control Association on national surveillance of wound and blood stream infections). A collaborative approach should provide better quality national data on all aspects of infection including antimicrobial resistance. AGAR surveys to date have mainly been limited to major teaching hospitals in capital cities. While we believe those results reflect the situation in those institutions, we have not attempted any population based surveys. Recent consolidation of pathology service provision and the availability of more flexible information technology may both serve to make such surveys a more practical possibility. Matching of data from such surveys to other information such as antimicrobial consumption may also be possible in future creating a powerful tool for monitoring the effectiveness of initiatives aimed at encouraging rational prescribing.

Continued funding of AGAR is a vexed issue. While funding for the survey activities of AGAR has been primarily by the participating laboratories, one major pharmaceutical company sponsored biannual meetings of participants from 1986 to May 2002. AGAR must now identify stable ongoing sources of funds to enable it to continue its current program and where appropriate broaden the scope of its activities, for example in the area of community-acquired infection. Whether funding can be sourced from the pharmaceutical industry or from government remains to be seen. The former possibility may be problematic given the reduction in development and marketing of antimicrobials in recent years.

For 15 years AGAR has provided data on the evolution of antimicrobial resistance in major pathogens in Australia. In the future it is hoped AGAR will not only continue this important task but also broaden the range of its surveys to cover emerging resistance in all organisms of importance in community and health care-associated infection. Efforts need to be made to ensure sampling is representative of hospital and community trends, to correlate results with other relevant data and to disseminate results widely in a more timely manner.

Acknowledgment

Eli Lilly Australia Pty Ltd was the major sponsor of AGAR from 1986 to 2002. We also acknowledge the significant contribution by Mrs Pam Catanach.

References